Takeda Pharmaceutical reported ¥23.6B of remaining performance obligations at 31 Mar 2025, up 184% from a year earlier. That is 0.0 years of trailing revenue already under contract.
Twelve-month book-to-bill: 1.00, i.e. 1.00 of new orders for every 1 of revenue recognised.
Backlog growth minus revenue growth: +177 points — orders are running ahead of revenue.
The latest filed figure is more than 200 days old.
Takeda Pharmaceutical backlog history
Remaining performance obligations at each quarter end (bars) against trailing twelve-month revenue (line).
Amounts in JPY. Source: SEC XBRL filings.
Quarter end
Backlog (RPO)
TTM revenue
Coverage
Customer prepayments
31 Mar 2025
¥23.6B
¥4.58T
0.0 yrs
n/a
31 Mar 2024
¥8.30B
¥4.26T
0.0 yrs
n/a
31 Mar 2023
¥8.63B
¥4.03T
0.0 yrs
n/a
31 Mar 2022
¥50.9B
¥3.57T
0.0 yrs
n/a
31 Mar 2021
¥34.8B
¥3.20T
0.0 yrs
n/a
31 Mar 2020
¥5.79B
¥3.29T
0.0 yrs
n/a
31 Mar 2019
¥7.92B
¥2.10T
0.0 yrs
n/a
1 Apr 2018
¥4.86B
¥1.77T
0.0 yrs
n/a
Questions
What is Takeda Pharmaceutical's backlog?
Takeda Pharmaceutical reported ¥23.6B of remaining performance obligations at 31 Mar 2025, up 184% from a year earlier. That is 0.0 years of trailing revenue already under contract.
About these numbers
Remaining performance obligations (RPO) are revenue a company has contracted but not yet recognised, as reported in its SEC filings (XBRL tag RevenueRemainingPerformanceObligation). Coverage = backlog ÷ trailing twelve-month revenue. Book-to-bill = (change in backlog + revenue) ÷ revenue. Conversion = revenue recognised ÷ the backlog at the start of each quarter, summed over four quarters. Counterparty values come from company filings and releases.